{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"Plasma circulating nucleic acid (CNA) samples were analyzed for ALK kinase domain mutations by digital polymerase chain reaction (PCR) BEAMing technology. Number of participants with one or more ALK mutations is presented.","groups":[{"description":"This reporting arm includes all Phase 1 participants who had documented ALK rearrangement.","id":"OG000","title":"ALK Positive Population (Phase 1)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"CNA peripheral blood analysis set included all participants of the ITT analysis set who had at least 1 molecular biomarker assayed.","reportingStatus":"POSTED","timeFrame":"Screening (up to 28 days)","title":"Number of Participants With ALK Mutation Based on Plasma CNA Analysis (Phase 1)","type":"SECONDARY","unitOfMeasure":"Participants"}